Chronic obstructive pulmonary disease

References

• De Matteis S, Jarvis D, Darnton A, et al. The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort. Eur Respir J. 2019;54(1):1900186. doi:10.1183/13993003.00186-2019.
   Web of Science ®Google Scholar
• Doiron D, de Hoogh K, Probst-Hensch N, et al. Air pollution, lung function and COPD: results from the population-based UK Biobank study. Eur Respir J. 2019;54(1):1802140. doi:10.1183/13993003.02140-2018.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Balte PP, Schwartz JE, et al. Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality. JAMA. 2019;321(24):2438–2447. doi:10.1001/jama.2019.7233.
   PubMed Web of Science ®Google Scholar
• Wan ES, Fortis S, Regan EA, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med. 2018;198(11):1397–1405. doi:10.1164/rccm.201804-0663OC.
   PubMed Web of Science ®Google Scholar
• Kirby M, Tanabe N, Tan WC, et al. Total airway count on computed tomography and the risk of chronic obstructive pulmonary disease progression. Findings from a population-based study. Am J Respir Crit Care Med. 2018;197(1):56–65. doi:10.1164/rccm.201704-0692OC.
   PubMed Web of Science ®Google Scholar
• Topalovic M, Das N, Burgel P-R, et al. Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. Eur Respir J. 2019;53(4):1801660. doi:10.1183/13993003.01660-2018.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Can J Respir Crit Care & Sleep Med. 2019;3(4):210–232. doi:10.1080/24745332.2019.1668652.
   Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Resp Med. 2019;7(9):745–756. doi:10.1016/S2213-2600(19)30190-0.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Resp Med. 2018;6(11):855–862. doi:10.1016/S2213-2600(18)30368-0.
   Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent S-M, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): A randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. New Engl J Med. 2019;381(11):1023–34.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Resp Med. 2019:pii: S2213-2600(19)30338–8. doi:10.1016/S2213-2600(19)30338-8.
   Google Scholar
• Butler CC, Gillespie D, White P, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 2019;381(2):111–120. doi:10.1056/NEJMoa1803185.
   PubMed Web of Science ®Google Scholar
• Devereux G, Cotton S, Fielding S, et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: A randomized clinical trial. JAMA. 2018;320(15):1548–1559. doi:10.1001/jama.2018.14432.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019;381(24):2304–2314. doi:10.1056/NEJMoa1908142.
   PubMed Web of Science ®Google Scholar
• Walker PP, Pompilio PP, Zanaboni P, Bergmo TS, et al. Telemonitoring in chronic obstructive pulmonary disease (CHROMED). A randomized clinical trial. Am J Respir Crit Care Med. 2018;198(5):620–628. doi:10.1164/rccm.201712-2404OC.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Delage A, Voelker K, et al. Improving lung function in severe heterogenous emphysema with the Spiration® valve system (EMPROVE): A multicenter, open-label, randomized, controlled clinical trial. Am J Resp Crit Care. 2019;200(11):1354–62.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Sue R, Wright S, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198(9):1151–1164. doi:10.1164/rccm.201803-0590OC.
   PubMed Web of Science ®Google Scholar